Natera Secures Expanded Medicare Coverage for Prospera Transplant Monitoring
Event summary
- Finalized MolDx LCD L40060 expands coverage for Natera's Prospera transplant rejection monitoring tests, effective August 30, 2026.
- Coverage increased from draft proposal: kidney (6/year in year 1 → 4/years 2-3), heart/lung (12/year in year 1 → 4/years 2-3).
- Policy revision follows advocacy by major transplant societies including ASTS, AST, and ISHLT.
- Original draft LCD proposed significantly lower test frequency across all indications.
The big picture
This LCD revision represents a significant win for precision medicine in organ transplantation, aligning Medicare policy with clinical guidelines advocated by major medical societies. The expanded coverage suggests growing recognition of molecular testing's value in preventing transplant rejection and preserving donor organs. For Natera, this could translate to meaningful revenue growth as Prospera becomes more widely adopted in post-transplant monitoring.
What we're watching
- Adoption Dynamics
- How quickly transplant centers will integrate the expanded testing protocol into standard care.
- Revenue Impact
- Whether the coverage expansion will materially increase Natera's test volume and revenue from organ transplant monitoring.
- Competitive Response
- How competitors in molecular diagnostics may react to this favorable coverage determination for Prospera.
Related topics